First patient in PropAngio-trial for angiosarcoma

A publication by scientists of the Anticancer Fund

CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infltrating lymphocytes in ovarian cancer

Christina Friese, Katja Harbst, Troels Holz Borch, Marie Christine Wulff Westergaard, Magnus Pedersen, Anders Kverneland, Göran Jönsson, Marco Donia, Inge Marie Svane, Özcan Met. CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer. Sci Rep. 2020; 10: 3914. Published online 2020 Mar 3. doi: 10.1038/s41598-020-60738-4.

Feedback on Europe's Beating Cancer Plan

Discover our Annual Impact Sheet 2019

How to teach an old medicine new tricks

A publication by scientists of the Anticancer Fund

Challenges and opportunities for cancer clinical trials in low- and middle-income countries

Bishal Gyawali, Gauthier Bouche, Nigel Crisp and Nicolas André. Challenges and opportunities for cancer clinical trials in low- and middle-income countries. Nature Cancer, 17 February 2020, DOI: 10.1038/s43018-020-0030-x

Cancer knows no boundaries, and neither do we

A publication by scientists of the Anticancer Fund

Nitroglycerin as a radiosensitizer in non-small cell lung cancer: Results of a prospective imaging-based phase II trial

Bart J.T. Reymen, Marike W. van Gisbergen, Aniek J.G. Even, Catharina M.L. Zegers, Marco Das, Erik Vegt, Joachim E. Wildberger, Felix M. Mottaghy, Ala Yaromina, Ludwig J. Dubois, Wouter van Elmpt, Dirk De Ruysscher, Philippe Lambin - Nitroglycerin as a radiosensitizer in non-small cell lung cancer: Results of a prospective imaging-based phase II trial. Clinical and Translational Radiation Oncology, 21 (49-55), DOI: 10.1016/j.ctro.2019.12.002